AlphAIalphai — Financial news for AI agents
thestarphoenix.comJUL 286 min read$TLRY

Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness

Tilray Brands (Nasdaq: TLRY) reported fiscal 2026 results for the year ended May 31, 2026. Net revenue rose 11% to $915.5M and adjusted EBITDA increased to $61.1M. International medical cannabis revenue grew 34%. The company said it ended with about $235M cash and net debt of $0.7M, and guided fiscal 2027 adjusted EBITDA of $68M to $75M.

Original reporting
thestarphoenix.com
Published Jul 28, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness — source image
Source · thestarphoenix.com
Decision brief

The 30-second read

$TLRYBullishMed
01

Why it matters

The key tradable elements are the record fiscal 2026 financials and the explicit FY2027 adjusted EBITDA guidance range, which can drive estimate revisions and near-term sentiment.

02

Market read

Record profitability metrics plus next-year EBITDA guidance create a clear basis for traders to reprice TLRY and adjust expectations for growth and cash generation.

03

What to watch

Adjusted EBITDA is influenced by non-cash charges and fuel surcharge elimination; traders may discount quality of earnings and watch for working-capital and cash-flow sustainability beyond the reported adjustments.

Relevance 8/10Novelty 7/10Timing: after-hours fiscal Q4 and full-fiscal-year results, with FY2027 EBITDA guidance

Background

Tilray is positioning itself as a diversified cannabis, beverage, hospitality, and wellness platform, with Europe medical distribution as a core growth engine and BrewDog as the beverage expansion catalyst.

Company-level read

Ticker impact

$TLRYBullishMedium confidence
Context

Tilray reported record fiscal 2026 revenue and adjusted EBITDA, plus fiscal 2027 adjusted EBITDA guidance of $68M to $75M.

Expected impact

Moderately positive near-term reaction likely, with follow-through tied to whether the $68M to $75M EBITDA range is above consensus and sustained cash generation.

Evidence & confidence

The article discloses a full-year results set (revenue, margins, adjusted EBITDA) and a specific next-year EBITDA range, which are direct inputs to valuation and positioning.

Market effects

Sector

Provides a datapoint that diversified cannabis-adjacent platforms can show margin stability and cash-flow improvement, potentially supporting sector sentiment.

Regional

Highlights Europe medical cannabis distribution growth, which may influence regional investor perception of regulated-market scalability.

Global

BrewDog acquisition and Carlsberg partnership narrative reinforces cross-border beverage platform integration as a growth driver.

Counterpoint

What could challenge this read

Beverage gross margin declined for fiscal 2026 (36% vs 39%), so the consolidated improvement may rely on mix and distribution gains rather than broad-based margin expansion.

Key entities

  • company
    Tilray Brands, Inc.

    Reported record fiscal 2026 revenue and adjusted EBITDA, and issued FY2027 adjusted EBITDA guidance of $68M to $75M.

  • acquired business
    BrewDog

    Acquisition is cited as igniting Tilray’s beverage platform expansion and stabilization efforts.

  • partner
    Carlsberg

    Mentioned as part of Tilray’s beverage platform via an exclusive U.S. partnership.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 7
$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

simplywall.st7 min
JUL 30
$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

yahoo.com6 min
JUL 29
$TLRYMed

Tilray Brands reports record US$915.5M revenue in Fiscal 2026

Tilray Brands reported record fiscal 2026 revenue of US$915.5M, up 11% from US$821.3M, driven by cannabis, beverage, distribution and wellness. Beverage net revenue rose 6% to US$254.0M, with Q4 beverage revenue up 61% to US$105M. Adjusted EBITDA increased to US$61.1M. Tilray completed a £33M BrewDog acquisition in March. It forecasts fiscal 2027 adjusted EBITDA of US$68M to US$75M.

foodbusinessmea.com4 min
JUL 29
$TLRYMedAI 8/10

Tilray Brands Q4 revenue beats estimates by 10.7%, shares rise 2.23%

Tilray Brands reported Q4 net revenue of $281.7 million for the period ended May 31, up 10.7% versus the $254.53 million consensus estimate, and shares rose 2.23% to $4.12 after hours. Adjusted EPS was $0.05, missing the $0.21 consensus. For FY26, net revenue rose 11% to $915.5 million; adjusted EBITDA increased to $61.1 million.

scanx.trade4 min